Osso VR, which uses Oculus Quest headsets to provide VR tools and content for surgical and medical device training, raises $14M Series A
Jonathan Shieber / TechCrunch :
Context & Ripple Effects
Osso VR's $14M Series A is the opening round of what becomes one of the fastest funding ladders in VR health care: within eighteen months comes a $27M round led by GSR Ventures, and by early 2022 a $66M Series C led by Oak HC/FT lifts total funding to about $109M. The bet rests on standalone hardware — Oculus Quest headsets remove the PC and cables that made surgical simulation costly to deploy.
First-order effects
- Osso VR gets capital to scale its Quest-based surgical and medical device training content, betting on headsets that hospitals can buy off the shelf rather than custom sim rigs.
- Device makers gain a training channel tied to a consumer headset, since Osso VR's platform packages both tools and content for surgical product education.
Second-order effects
- Rival simulation platforms are forced to chase comparable rounds: FundamentalVR follows with a $20M raise led by EQT Life Sciences, confirming investor appetite for cross-platform medical training.
- Oculus Quest's enterprise story shifts from gaming — where Quest content spending was already climbing — toward verticals like medicine, giving Meta's hardware a second demand curve.
Third-order effects
- If the funding cadence holds across Osso VR, FundamentalVR, and adjacent players like Oxford VR's mental-health simulations and Vicarious Surgical's robot-VR surgery, medical VR consolidates from novelty pilots into a distinct funded category competing with legacy cadaver-and-box trainers.
The trend: Standalone headsets are pulling clinical simulation from hospital labs into venture-backed software companies, with each successive round raising the bar for category entrants.